Emtricitabine/Rilpivirine/Tenofovir alafenamide fixed-dose combination
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Emtricitabine/Rilpivirine/Tenofovir alafenamide fixed-dose combination, covering 2017-12-08 to 2017-12-08. Get the full timeline:
Most recent: Clinical Trial Update: Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) [Phase 3]